Cargando…

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis

BACKGROUND: Factors influencing differential responses of prostate tumors to androgen receptor (AR) axis-directed therapeutics are poorly understood, and predictors of treatment efficacy are needed. We hypothesized that the efficacy of inhibiting DHT ligand synthesis would associate with intra-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mostaghel, Elahe A., Morgan, Andrew, Zhang, Xiaotun, Marck, Brett T., Xia, Jing, Hunter-Merrill, Rachel, Gulati, Roman, Plymate, Stephen, Vessella, Robert L., Corey, Eva, Higano, Celestia S., Matsumoto, Alvin M., Montgomery, R. Bruce, Nelson, Peter S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214744/ https://www.ncbi.nlm.nih.gov/pubmed/25356728 http://dx.doi.org/10.1371/journal.pone.0111545

Ejemplares similares

LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
por: Nguyen, Holly M., et al.
Publicado: (2017)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors
por: Qu, Xiaoyu, et al.
Publicado: (2013)

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
por: Nyquist, Michael D., et al.
Publicado: (2023)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors
por: Mostaghel, Elahe A., et al.
Publicado: (2012)

Statins and adrenal androgen levels in prostate cancer: A new twist
por: Mostaghel, Elahe A
Publicado: (2021)

Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation
por: Mostaghel, Elahe A
Publicado: (2014)

Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
por: Alsinnawi, Mazen, et al.
Publicado: (2019)

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
por: Hirata, Yoshito, et al.
Publicado: (2018)

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
por: Montgomery, Bruce, et al.
Publicado: (2010)

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions
por: Mohammad, Osama S., et al.
Publicado: (2017)

Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study
por: Cherrier, Monique M, et al.
Publicado: (2010)

SAT-114 Loss of DHEA-Targeting SULT2b1b Sulfotransferase Exacerbates Aggressive Traits of Prostate Cancer
por: Song, Chung Seog, et al.
Publicado: (2020)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Potential use of custirsen to treat prostate cancer
por: Higano, Celestia S
Publicado: (2013)

Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer
por: Kumar, Akash, et al.
Publicado: (2016)

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
por: Henzler, Christine, et al.
Publicado: (2016)

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
por: Gross, Mitchell, et al.
Publicado: (2007)

Glucocorticoids and prostate cancer treatment: friend or foe?
por: Montgomery, Bruce, et al.
Publicado: (2014)

Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes
por: Gordon, Ryan R., et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Steroid hormone synthetic pathways in prostate cancer
por: Mostaghel, Elahe A.
Publicado: (2013)

Intracrine androgen biosynthesis and drug resistance
por: Penning, Trevor M., et al.
Publicado: (2020)

Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples’ Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach
por: Bossio, Jennifer A., et al.
Publicado: (2021)

Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors
por: Cherrier, Monique M., et al.
Publicado: (2021)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

The androgen receptor mediates antiapoptotic function in myometrial cells
por: Li, H, et al.
Publicado: (2014)

Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain
por: Uo, T, et al.
Publicado: (2017)

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation
por: Graff, Julie N, et al.
Publicado: (2015)

Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants
por: Minaiyan, Mohsen, et al.
Publicado: (2012)

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

Assessing the nutritional needs of men with prostate cancer
por: McLaughlin, Kaitlin, et al.
Publicado: (2019)

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Harnessing Solute Carrier Transporters for Precision Oncology
por: Nyquist, Michael D., et al.
Publicado: (2017)

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
por: Cao, Bo, et al.
Publicado: (2014)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sb8f43er8es8bh0lunv147g7su